

1 **Increased *Akkermansia* abundance is associated with increased colonic mucosal ω -3 fatty acids and**
2 **decreased colonic mucosal PGE₂ concentrations following healthy dietary pattern interventions**

3
4 **S.B. Rifkin¹, A. Sen², D.K. Turgeon¹, R. Chan^{2,3}, M.T. Ruffin⁴, D.E. Brenner¹, P.D. Schloss⁵, Z.**
5 **Djuric²**

- 6
7
8
9 1. Michigan Medicine Department of Internal Medicine, Ann Arbor, 48109, USA.
10 2. Michigan Medicine Department of Family Medicine, Ann Arbor, 48109, USA.
11 3. Present address:10X Genomics, San Francisco, CA 94111
12 4. Penn State Cancer Institute, Hershey, PA, 17033, USA.
13 5. Michigan Medicine Department of Immunology and Microbiology, Ann Arbor, MI, 48109,USA

14
15 **Corresponding author:**

16 Samara B Rifkin, MD, ScM
17 Division of Gastroenterology and Hepatology
18 University of Michigan School of Medicine
19 srifkin@med.umich.edu

20
21 **Short title:** colonic ω -3 fatty acids and *Akkermansia*

22
23 **Keywords:** ω -3 polyunsaturated fatty acids (ω -3 PUFA), prostaglandin E₂ (PGE₂), cyclooxygenase
24 (COX) -1 and COX-2, *Akkermansia*

52 ABSTRACT

53 Both increased dietary intake of ω -3 polyunsaturated fatty acids (PUFA) and subsequent increases in
54 colonic mucosal ω -3 PUFA concentrations have been linked to improved gut barrier function and
55 decreased risks of metabolic diseases and cancer. In addition, increased dietary ω -3 PUFA has been
56 linked to eubiosis in mouse studies. Increased ω -3 PUFA function in part to reduce cyclooxygenase-
57 (COX) mediated prostaglandin E₂ (PGE₂) production, a biomarker of cancer risk linked to compromised
58 gut barrier function. We analyzed data from a dietary intervention study in individuals at increased risk of
59 colon cancer to determine whether changes in the mucosal microbiome composition were associated with
60 changes in colonic mucosal ω -3/ ω -6- PUFA ratio. Microbiome analyses of colonic biopsies before and
61 after the dietary intervention from 86 participants were done by sequencing the V4 region of the 16S
62 rRNA gene. Multivariable linear regression models were used to evaluate further whether changes in
63 *Akkermansia* was associated with changes in each colonic tissue variable: ω -3/ ω -6 PUFA ratios, PGE₂
64 concentrations, and expression of COX-1 and COX-2. The median dietary intake and mucosal ω -3/ ω -6
65 PUFA ratio increased after intervention. Greater increases in mucosal ω -3/ ω -6 PUFA ratios after
66 intervention were significantly associated with several changes in taxon abundance, including increased
67 *Akkermansia muciniphilia* relative abundance. An increased abundance of *Akkermansia muciniphilia* also
68 was associated significantly with decreased PGE₂ concentrations but not with changes in COX
69 expression. Further studies are warranted to elucidate mechanisms by which *Akkermansia* may affect or is
70 affected by these pathways and the relative importance of individual dietary components.

71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102

103 Introduction

104
105 Chronic low grade inflammation has been implicated in the rising prevalence of chronic diseases
106 including obesity, diabetes, cardiovascular diseases and cancer.^{1,2} It has been suggested that Western
107 diets containing relatively high saturated fatty acids and ω -6 polyunsaturated fatty acids (PUFA) but low
108 monounsaturated fatty acids (MUFA) and ω -3 PUFA contribute to pro-inflammatory states and the rising
109 prevalence of chronic diseases.³ In particular, consumption of ω -3 PUFA from fish and other foods
110 results in a more favorable eicosanoid profile to reverse the chronic inflammation associated with reduced
111 risks of obesity, diabetes and cancer.⁴⁻⁶ Dietary fats, however, have multi-faceted effects on inflammation
112 and chronic diseases that also appears to include changes in the microbiome and gut barrier function.²

113
114 High saturated fat diets have been shown to compromise gut barrier function through mucus thinning and
115 loss of junction barrier proteins leading to metabolic endotoxemia.^{2,7,8} Systemic exposures to bacterial
116 lipopolysaccharides (LPS) are thought to mediate this process. LPS, a major component of the gram
117 negative bacterial outer membrane, can be absorbed into the bloodstream to stimulate toll like receptor 4
118 (TLR4) with reactive elevations in serum pro-inflammatory eicosanoids and cytokines.^{2,8,9} Conversely,
119 certain anti-inflammatory dietary components, including ω -3 PUFA, have been shown to prevent or
120 reverse metabolic endotoxemia and chronic low grade inflammation by improving gut barrier
121 function.^{2,8,10}

122
123 Dietary ω -3 PUFA affect gut barrier function by several mechanisms. The ω -3 PUFA inhibit formation of
124 pro-inflammatory eicosanoids such as prostaglandin E₂ (PGE₂) from the cyclooxygenase (COX-1) and
125 COX-2-mediated oxidation of arachidonic acid (AA), and the reduction in PGE₂ signaling reduces local
126 inflammatory reactions to maintain normal barrier function.¹¹ The ω -3 PUFA compete with AA as
127 substrates for COX-1 and COX-2 enzymes and eicosapentaenoic acid ω -3 (EPA) also binds to COX-1 to
128 allosterically inhibit AA oxygenation.¹² In addition, ω -3 PUFA may prevent inflammation by
129 influencing microbiome composition.¹³ A preponderance of studies have found that ω -3 PUFA
130 administration increases LPS-suppressing bacteria including *Akkermansia mucinophila*.^{2,10,14-19} Increased
131 tissue ω -3 PUFA in a transgenic mouse model that endogenously produces ω -3 PUFA led to lower levels
132 of LPS-producing bacteria and higher levels of LPS-suppressing bacteria versus that in wild type
133 mice.^{10,14} In human studies, the presence of *A. mucinophila* in the outer mucus layer of the colon was
134 associated with reduction of metabolic endotoxemia and chronic low-grade inflammation brought on by
135 high fat diet and obesity. These beneficial effects were attributed to the role of *A. mucinophila* in
136 maintaining gut barrier function.¹⁶

137

138 Most studies aimed at investigating the relationship between PUFAs and intestinal microbiome
139 composition have quantified the intestinal microbiota in excreted stool and measured PUFAs in the
140 serum. Excreted stool, however, does not reflect the bacterial milieu adhering to the colonic mucosal
141 surface.²⁰ Bacteria adhering to the colonic mucin are in close proximity to the colon epithelial cells.
142 Therefore, characterizing the bacteria associated with the colonic mucosa may be more meaningful to
143 evaluate in the interaction between the diet and the gut microbiome. In the present study, we performed a
144 secondary analysis of a study that recruited individuals with an elevated risk of colorectal cancer and
145 randomized them to either a Healthy Eating diet or a Mediterranean diet. Both diet arms achieved similar
146 increases in median dietary and median colonic mucosal ω -3/ ω -6 PUFA ratios, but there was substantial
147 inter-individual variability in fatty acid changes within each arm. This afforded the opportunity to
148 evaluate whether changes in the colonic mucosal microbiome were associated with changes in colonic
149 mucosal ω -3/ ω -6 PUFA ratios. Because of its known role in promoting colonic integrity and limiting
150 metabolic endotoxemia, we investigated further whether *Akkermansia* abundance was associated with
151 colonic mucosal ω -3/ ω -6 PUFA ratio as well as colonic mucosal COX-1 and 2 gene expression and PGE₂
152 using multivariable linear regression models.

153

154 Methods

155

156 The Healthy Eating Study

157 Methods for conducting the Healthy Eating Study have been previously published.²¹ This study was
158 conducted according to the Declaration of Helsinki and all procedures involving human subjects were
159 approved by The University of Michigan Institutional Review Board (HUM00007622). This study was
160 registered at ClinicalTrials.gov (registration no. NCT00475722). In brief, 120 persons at increased risk of
161 colorectal cancer were enrolled from Ann Arbor, MI, and surrounding areas from July 2007 to November
162 2010. Increased risk was defined as having a family history of colorectal cancer in either one first-degree
163 relative or two second-degree relatives, or having a personal history of colorectal adenoma or cancer. All
164 study participants provided informed, signed consent prior to randomization.

165

166 A total of 94 participants completed 6 months of study. Participants underwent un-prepped flexible
167 sigmoidoscopy before and after the 6-month intervention. Eight colorectal biopsy samples were obtained
168 from the colon, 20 to 25 cm from the anal sphincter. Biopsy samples were flash frozen in liquid nitrogen
169 within 5 seconds and kept at -70°C until analysis. Colon biopsy samples were available
170 for microbiome analysis from 94 participants at baseline and from 86 participants after dietary

171 intervention. Blood was collected after an overnight fast and prepared serum was kept frozen at -80 °C
172 until analysis.

173

174 Measures of fatty acids, prostaglandin E₂, COX-1 and COX-2

175 Serum and colon biopsy samples were analyzed for complete fatty acid profiles as methyl esters using gas
176 chromatography—mass spectroscopy (GC-MS). ω -3 PUFA was calculated by summing 18:3, 20:5, and
177 22:6, whereas ω -6 PUFA was calculated by summing 18:2 (n6), 20:3 (n6), 20:4 (n6). The ratio was then
178 produced dividing ω -3 PUFA by ω -6 PUFA. PGE₂ in colon mucosal biopsy samples was analyzed using
179 liquid chromatography with mass spectrometry as previously described.¹² COX-1 and COX-2 gene
180 expression was quantified by Quantitative real-time PCR.²²

181

182 Dietary intervention

183 Participants were randomized to receive dietary counseling to follow either a Healthy Eating diet or a
184 Mediterranean diet and the specific details of the two dietary interventions have been published
185 previously.²¹ Overall, the change in dietary ω -3/ ω -6 PUFA ratios and colonic mucosal ω -3/ ω -6 PUFA
186 ratios were similar between the two study arms, however there was inter-individual variation in fatty acid
187 intakes and colonic tissue levels across the entire study population that allowed us to perform this
188 secondary data analysis.²¹

189

190 Dietary data was obtained at baseline and 6 months using two 24-hour recalls and two days of written
191 food records (four non-consecutive days per time point). The analysis of food records and recalls were
192 performed with the Nutrition Data System for Research (2013 version; University of Minnesota, Nutrition
193 Coordinating Center). Food and nutrient intakes were averaged over the four days of intake for each
194 subject at each time point.

195

196 Mucosal microbiome 16S rRNA sequencing and processing

197 DNA was isolated from biopsy samples using PowerMag Microbiome RNA/DNA Isolation Kit (Mo Bio
198 Laboratories, Inc) and epMotion 5075 liquid handling system (Eppendorf). The hypervariable V4 region
199 was amplified using primers described previously and 16S rRNA gene sequences were processed using
200 the mothur software package.²³ FASTQ files were generated for paired end reads. Paired-end reads were
201 merged into contigs, aligned to the SILVA 16S rRNA sequence database (version 138), and low quality
202 sequences and chimeras were removed.²⁴ Sequences were classified by training a naive Bayesian
203 classifier with a 16S rRNA gene training set (Ribosomal Database Project (RDP)).²⁵ Sequences were then
204 clustered into operational taxonomic units (OTUs) using a 97 % similarity cutoff with the OptiClust

205 clustering algorithm.²⁶ Samples were rarefied to 1,047 sequences per sample, which eliminated ten of 179
206 samples.

207

208 Statistical analysis

209 Individuals were categorized according to baseline colonic mucosal ω -3/ ω -6 PUFA ratios tertiles.

210 Baseline characteristics variables were tested for normality using the Shapiro-Wilk's method in R

211 (version 4.0.2), which did not follow a normal distribution. Therefore, these values were assessed using

212 medians and interquartile ranges for continuous variables, and as frequencies and percentages for

213 categorical variables. Additionally, fatty acid dietary intake, serum and colonic mucosal concentrations

214 before and after dietary intervention did not follow a normal distribution. We therefore calculated median

215 differences in these variables before and after intervention. Statistically significant changes in median

216 differences in nutrient variables were assessed using Wilcoxon signed rank test.

217

218 We characterized variation in microbial community using metrics for 1) α diversity (Shannon index) to

219 quantify intraindividual variation and 2) β -diversity-based distance metric (Bray-Curtis) to quantify the

220 distance between individuals. These values were calculated using mothur software package. We

221 compared Shannon index across serum, diet and colonic mucosal ω -3/ ω -6 PUFA ratios tertiles using

222 Kruskal-Wallis. Associations between microbiome variation and serum, diet and colonic mucosal ω -3/ ω -

223 6 PUFA ratios were assessed via permutational multivariate analysis of variance (PERMANOVA) both as

224 continuous variables and using variables categorized into tertiles. To visualize the Bray-Curtis distance

225 values between samples, Non-metric multidimensional scaling-NMDS was calculated and results were

226 plotted using the vegan package within the R program.

227

228 Linear regression was used to identify bacterial taxa whose relative abundance were associated with

229 changes in of serum, diet and colonic mucosal ω -3/ ω -6 PUFA ratios. The Benjamini-Hochberg (B-H)

230 method was used to adjust P values in the multiple correlation analyses while controlling for the expected

231 false discovery rate at 0.05. We then constructed a multivariable linear regression models for each colonic

232 mucosal variable (ω -3/ ω -6 PUFA ratio, PGE₂ levels, COX-1 and COX-2 gene expression) to assess if a

233 given colonic mucosal variable was associated with *Akkermansia* abundance. We modeled each colonic

234 mucosal variable (ω -3/ ω -6 PUFA ratio, PGE₂ levels, COX-1 and COX-2 gene expression) at 6 months as

235 a factor of log change in *Akkermansia* abundance levels after intervention, also adjusting for the colonic

236 mucosal variable at baseline and age, sex and body mass index (BMI).

237

238 Results

239 Baseline characteristics of study participants

240 The 86 study participants with sequenced biopsy samples available at one or both time points were 74%
241 female, had a median age of 54 years, and a median BMI of 27 kg/m². A small proportion of participants
242 (18%) were taking nonsteroidal anti-inflammatory drugs (NSAIDs). Baseline data are shown by tertiles of
243 colonic mucosal ω -3/ ω -6 PUFA ratios (Table 1). Age, BMI, sex, NSAID use, and PGE₂ were not
244 different across tertiles of colonic mucosal ω -3/ ω -6 PUFA ratios.

245

246 Effects of dietary intervention on fatty acid intake and concentrations

247 Median differences in fatty acid intake, serum and colonic mucosal concentrations after each dietary
248 intervention are shown in Table 2. Dietary ω -3 PUFA increased in the Healthy Eating arm (P=0.04),
249 while dietary ω -6 PUFA decreased in the Mediterranean arm (P<0.0001). The dietary ω -3/ ω -6 PUFA
250 ratio increased in both the Healthy Eating arm (P=0.01) and the Mediterranean arm (P=0.0002). Serum ω -
251 3 PUFA increased in the Healthy Eating arm (P=0.004) and serum ω -6 PUFA decreased in the
252 Mediterranean arm (P=0.04). The median serum ω -3/ ω -6 PUFA ratio remained the same in the Healthy
253 Eating arm and increased from 0.09 to 0.12 in the Mediterranean arm (P=0.03). Median colonic mucosal
254 PGE₂ concentrations did not change appreciably in the Healthy Eating arm (P=0.8) nor the Mediterranean
255 arm after 6 months of intervention (P=0.7). The colonic mucosal ω -3/ ω -6 PUFA ratio increased in both
256 the Healthy Eating arm (P=0.03) and the Mediterranean arm (P=0.001). We confirmed that both arms
257 achieved similar changes in colonic mucosal ω -3/ ω -6 PUFA ratio. However, there was substantial inter-
258 individual variation in colonic mucosal concentrations of all these analytes.

259

260 Effects of fatty acid concentrations on gut microbiota

261 To test the hypothesis that fatty acids can influence the microbiome, we examined how global
262 microbiome features, including within community variation (alpha diversity with Shannon index) and
263 between community variation (beta diversity using Bray-Curtis distance), varied according to colonic
264 mucosal, serum and dietary fatty acid levels.²² The Shannon index was inversely associated with baseline
265 colonic mucosal ω -3/ ω -6 PUFA (P=0.02), but not associated with serum ω -3/ ω -6 PUFA ratio at baseline
266 nor any of these variables at 6 months after intervention (Figure 1).

267

268 When we performed PERMANOVA analysis, we found no differences in beta diversity or community
269 distance according to diet (P= 0.5), or colonic mucosal ω -3/ ω -6 PUFA ratio at 6 months (P= 0.1),
270 however serum ω -3/ ω -6 PUFA ratio at 6 months showed a stronger association with beta diversity
271 (P=0.003). We also performed PERMANOVA analysis using dietary (P=1.00), serum (P=0.09) and
272 colonic mucosal ω -3/ ω -6 PUFA ratio (P= 0.46) categorized into tertiles and found no differences in beta

273 diversity (see Figure 2). We found that when we performed pairwise PERMANOVA on serum ω -3/ ω -6
274 PUFA ratio levels tertiles at 6 months that none of the differences were significant (P=0.5).

275

276 Abundance of taxa by colonic mucosal, serum and dietary ω -3/ ω -6 PUFA ratios at baseline

277 We identified several differentially abundant genera that were positively associated with baseline colonic
278 mucosal ω -3/ ω -6 PUFA ratio including *Varibaculum*, *Rhizobium*, *Porphyromonas*, *Mogibacterium*,
279 *Megamonas*, *Coprobacillus*, *Butyricoccus*, *Actinomyces* and unclassified members of
280 *Erysipelotrichaceae*. Unclassified members of *Lachnospiraceae* were negatively associated with ω -3/ ω -6
281 PUFA ratio (Figure 3).

282

283 The following genera were positively associated with baseline serum ω -3/ ω -6 PUFA ratio (Figure 3):

284 *Rothia*, *Phyllobacterium*, *Negativicoccus*, *Leuconostoc*, *Hydrogenoanaerobacterium*, *Enterococcus*,
285 *Clostridium sensu stricto*, *Cloacibacterium*, *Brochothrix* and unclassified members of *Proteobacteria* and
286 *Actinobacteria*. *Rothia*, *Phyllobacterium*, *Enterococcus*, *Coprobacillus*, *Butyricoccus*, *Brochothrix*,
287 *Anaeotruncus* and unclassified member of *Actinobacteria* were positively associated with dietary ω -3/ ω -6
288 PUFA ratio levels.

289

290 Abundance of taxa by colonic mucosal, serum and dietary ω -3/ ω -6 PUFA ratios after 6 months

291 We identified several differentially abundant genera whose relative abundance were positively associated
292 with colonic mucosal ω -3/ ω -6 PUFA ratio including unclassified members of *Alphaproteobacteria*,
293 *Clostridia* and *Lachnospiraceae*, and *Akkermansia* at 6 months. *Odoribacter* was negatively associated
294 with colonic mucosal ω -3/ ω -6 PUFA ratio at 6 months (Figure 3).

295

296 The following genera were positively associated with serum ω -3/ ω -6 PUFA ratio (Figure 3):

297 *Varibaculum*, *Acinetobacter*, *Arcanobacterium*, *Stentotrophomonas*, *Streptococcus*, *Actinobaculum*,
298 *Actinomyces*, *Subdoligranulum*, and unclassified members of *Betaproteobacteria*, while *Blautia*, *Dorea*
299 and *Bifidobacterium* were negatively associated at 6 months. *Veillonella*, *Streptococcus*, *Butyricoccus*,
300 *Helococcus* and unclassified members of *Clostridiales* were positively associated with dietary ω -3/ ω -6
301 PUFA ratio levels.

302

303 *Akkermansia* abundance and colonic mucosal ω -3/ ω -6 PUFA ratio, COX gene expression, PGE₂ 304 concentration

305 We further investigated whether *Akkermansia* abundance was associated with colonic mucosal ω -3/ ω -6
306 PUFA ratio as well as colonic mucosal COX-1 and 2 gene expression, PGE₂ levels adjusting for age,

307 BMI, sex and dietary ω -3/ ω -6 PUFA ratio intake. COX-1 and COX-2 were not associated with ω -3/ ω -6
308 PUFA ratio. We investigated whether these colonic mucosal nutrient concentrations, gene expression and
309 metabolite concentrations were associated with levels of *Akkermansia* abundance using two different
310 linear models.

311
312 To assess the effect of change in *Akkermansia* abundance on colonic mucosal ω -3/ ω -6 PUFA ratio, PGE₂,
313 COX-1 and COX-2 gene expression following the dietary intervention, we modeled each colonic mucosal
314 variable at 6 months as the dependent variable adjusting for each colonic mucosal variable at baseline and
315 change in *Akkermansia* abundance using linear regression (Table 3). We found that a positive log change
316 in *Akkermansia* following the dietary intervention was significantly associated with increased colonic
317 mucosal ω -3/ ω -6 PUFA ratios at 6 months after adjusting for age, sex, BMI, and dietary ω -3/ ω -6 PUFA
318 ratios (P=0.02). When we modeled colonic mucosal PGE₂ at 6 months with adjustment for baseline
319 values, a negative log change in *Akkermansia* following the intervention conversely was associated with a
320 positive change in colonic mucosal PGE₂ (P=0.01). COX-1 or COX-2 expression at 6 months were not
321 associated with log change in *Akkermansia* abundance (P=0.3) and (P=0.5), respectively.

322

323 Discussion

324 The two dietary intervention arms resulted in similar changes in serum and colonic mucosal ω -3/ ω -6
325 PUFA ratios (Table 2). We therefore analyzed changes in colonic mucosal measures and in bacterial
326 populations in all 86 study participants combined. The colonic mucosal ω -3/ ω -6 PUFA ratio increased in
327 the combined study population. Overall, we found that differences in PUFA incorporated in colonic
328 tissues were not associated with global changes in the microbiome, but they were associated with specific
329 microbiome changes. Alpha diversity, i.e. within community diversity, was associated with colonic
330 mucosal ω -3/ ω -6 PUFA ratios at baseline, but otherwise not associated with dietary or serum ω -3/ ω -6
331 PUFA ratio at baseline or any nutrient ratios at 6 months (Figure 1). Beta diversity, i.e. inter-sample
332 diversity, varied according to serum but not colonic mucosal ω -3/ ω -6 PUFA concentration at 6 months
333 (Figure 2). Our results analyzing differential taxon abundance associated with changes in ω -3/ ω -6 PUFA
334 ratio are consistent with both mouse studies and clinical interventions, which also found that higher ω -3
335 PUFA levels may influence the abundance of short chain fatty acid (SCFA) producing bacteria.^{10,15,17-}
336^{19,27,28} Several studies involving ω -3 supplementation reported increases in SCFA-producing
337 bacteria.^{15,17,19,29,30} We also found a positive association between *Lachnospiraceae* and colonic mucosal ω -
338 3/ ω -6 PUFA ratios, but an inverse association with *Odoribacter*, both producers of SCFA (Figure 3).

339

340 In subsequent analyses, we focused on the association between *Akkermansia* abundance and colonic
341 mucosal ω -3/ ω -6 PUFA ratio concentrations that had emerged in taxon-wide analyses since a lot of
342 information is available on the role of *Akkermansia muciniphilia* in colon health.^{1,8,16} In addition to
343 colonic mucosal PUFA, we explored the association between *Akkermansia* abundance and PGE₂, a pro-
344 inflammatory mediator in the colon.³¹ PGE₂ is produced from COX-mediated oxygenation of arachidonic
345 acid, an ω -6 PUFA. We found that increased abundance of the *A. muciniphilia* after 6 months of dietary
346 intervention was significantly and independently associated with increased colonic mucosal ω -3/ ω -6
347 PUFA ratios and with decreased PGE₂ concentrations using two different types of linear models,
348 adjusting for age, sex and BMI. This did not appear to be due to changes in COX-1 or COX-2 expression
349 in colonic biopsy tissues.

350

351 *A. muciniphilia* is found within the mucin layer and therefore is likely to impact the gut barrier function.
352 Higher levels of *Akkermansia* abundance have been linked to decreased serum LPS levels, improved
353 insulin resistance and low grade chronic inflammation¹⁶ While obesity and high fat diets were associated
354 with decreased levels of *Akkermansia* abundance, *Akkermansia* supplementation improved metabolic
355 endotoxemia, hyperglycemia, and adiposity in mice fed a high fat diet.¹⁶ Additionally, *Akkermansia* is
356 enriched in people who consume other diets that are known to enhance barrier function and improve
357 metabolic endotoxemia, including general anti-inflammatory dietary patterns and functional foods rich in
358 polyphenols including extracts of black raspberry, concord grape and cranberry.^{2,32-36}

359

360 Our findings of increased *Akkermansia* levels with higher colonic tissue ω -3/ ω -6 PUFA ratios are
361 compatible with prior animal studies and clinical interventions.^{9,14,17,18} Several murine models have also
362 demonstrated that fish oil supplementation resulting in increased colonic mucosal ω -3/ ω -6 ratios led to
363 higher *Akkermansia* abundance levels, among other taxon.^{9,14,18} The association between *Akkermansia* and
364 two variables in the same pathway in the expected directions makes a stronger argument for a causal
365 relationship, however we did not find an association between increased ω -3/ ω -6 PUFA ratios and
366 decreased PGE₂ concentrations following the dietary intervention. Furthermore, the association between
367 PGE₂ and *Akkermansia* abundance was not weakened when ω -3/ ω -6 PUFA ratio was included in the
368 model.

369

370 While there is accumulating evidence that colonic ω -3 PUFA may modify the colonic milieu and
371 encourage the growth of *Akkermansia*, it is unclear how *Akkermansia* abundance may be influencing
372 colonic mucosal PGE₂ levels or vice versa. A relevant mouse study demonstrated that increased SCFA
373 levels promoted an increased PGE₁/PGE₂ ratio that in turn stimulated myofibroblast to express MUC-2,

374 an important component of barrier integrity.³⁷ Conversely, another mouse study found that increased
375 PGE₂ through its receptor EP4 reduced SCFA-producing bacteria leading to repression of intestinal Treg
376 accumulation and accumulation of intestinal inflammation.³⁸ While we speculate that colonic mucosal
377 PUFA may influence the mucosal adherent microbiome, but the reverse or both directions could be true.
378 Furthermore, we hypothesize that *Akkermansia* abundance may lead to improved gut barrier function and
379 limit PGE₂ production, but the reverse could be true. Therefore, the direction of the proposed effect
380 cannot be determined from a statistical model and should also be interpreted with caution.

381
382 Both increased ω -3 PUFA and *A. muciniphilia* may alleviate the pathogenesis of obesity and high
383 saturated fat diet on chronic low grade inflammation by limiting metabolic endotoxemia and
384 strengthening gut barrier function.^{16,39} In transgenic fat-1 mice that endogenously convert ω -6 PUFA to
385 ω -3 PUFA, transgenic fat-1 mice harbored lower levels of LPS producing bacteria and higher levels of
386 LPS-suppressing bacteria (*Bifidobacterium*, *A. muciniphilia*) as compared with wild type mice.¹⁴ These
387 mice also demonstrated increased expression of intestinal alkaline phosphatase (IAP), an anti-
388 inflammatory enzyme located on the brush border that protects against pathogenic bacteria. Notably IAP
389 promotes anti-inflammatory effects on the GI mucosa by dephosphorylating microbial LPS and
390 microbiota-produced ATP, an important inflammatory mediator.¹⁴ IAP has also been linked to improved
391 gut barrier function and has been shown to alleviate metabolic disease.^{14,40} The authors hypothesized that
392 increased tissue ratio of ω -3/ ω -6 PUFA ratios led to increased expression of IAP which cultivated an
393 intestinal milieu favoring growth of LPS-suppressing bacteria.¹⁴

394
395 One strength of this study is the availability of colonic tissue for the fatty acid measures. Few studies
396 have assessed the effect of colonic mucosal ω -3 PUFA on microbiome, and most studies have relied on
397 self-reported diet, serum or RBC concentrations of ω -3 PUFA. Fatty acids are absorbed efficiently by the
398 proximal small intestine with little residual traveling to the colon to affect the luminal microbiome
399 composition.⁴¹ Therefore, the PUFA composition of colonic tissue more likely influences microbiome
400 composition via indirect effects on the nature of the colonic barrier. The beneficial effects of colonic
401 mucosal ω -3 PUFA have been shown to be manifested in part due to improved gut barrier function in
402 both animal models and human intervention studies.^{39,42} In addition, our study also sequenced the
403 microbiome adhering to colonic mucosal biopsies. Colonic mucosal fatty acids are more likely to affect
404 bacteria associated with the mucosa, such as *A. muciniphilia*, a bacterium known to reside in the mucin in
405 close proximity to the mucosa.

406

407 There are also several limitations to this study that should be recognized. The data in this study was
408 analyzed using 16S rRNA and therefore our ability to determine changes in microbial function is limited.
409 In addition, 16S rRNA analysis only allows resolution to the genus level. However, *A. muciniphilia* is the
410 only bacterium of its genus known to colonize humans and therefore misclassification for this finding is
411 unlikely. Lastly, sample size limited our ability to adjust for multiple covariates simultaneously.

412

413 In summary, we report a positive association between mucosal *Akkermansia* abundance and colonic tissue
414 ω -3/ ω -6 PUFA ratios and a negative association with colonic PGE₂ concentrations in subjects who had
415 undergone dietary intervention, either Mediterranean or Healthy Eating, both of which resulted in similar
416 dietary changes with the exception of monounsaturated fats. These results are consistent with animal
417 models and human studies that provide accumulating evidence of a connection between ω -3 PUFA and
418 increased *Akkermansia* abundance on gut barrier function. Our growing understanding of how both ω -3
419 PUFA and *Akkermansia* improve gut barrier function and potentially limit metabolic endotoxemia is
420 compelling as a causal association between diet, microbiome and chronic low-grade inflammation. Future
421 studies exploring the effect of colonic mucosal ω -3/ ω -6 PUFA ratios on the microbiome, on *A.*
422 *muciniphilia* in particular, and gut barrier function are warranted.

423

424

425

426

427

428 **Acknowledgements**

429
430 We thank all the individuals who volunteered to participate in the Healthy Eating Study. We acknowledge
431 the contributions of Maria Cornellier in conducting the dietary counseling, Mary Rapai for study
432 recruitment and coordination, Dr. Elkhansa Sidahmed for carrying out the gene expression analyses, Faith
433 Umoh for carrying out the assays for LBP, and Jianwei Ren for the analyses of fatty acids, carotenoids
434 and eicosanoids.

435
436 **Financial Support**

437
438 We acknowledge support from the University of Michigan Medical School Host Microbiome Initiative
439 and NIH grants RO1 CA120381, Cancer Center Support Grant P30 CA046592, and the Rose and
440 Lawrence C. Page, Sr. Family Charitable Foundation (to Dr. D. Kim Turgeon). Rena Chan was supported
441 by the Cancer Biology Training Program grant T32 CA009676. The research used core resources
442 supported by a Clinical Translational Science Award, NIH grant UL1RR024986 (the Michigan Clinical
443 Research Unit), by the Michigan Diabetes Research Center, NIH grant 5P60 DK20572 (Chemistry
444 Laboratory), the Michigan Nutrition and Obesity Research Center, and NIH grant P30 DK089503.

445 **Conflict of Interest**

446 The authors have no financial, professional or personal conflicts of interest to disclose.

447 **Authors' contributions:**

448 SR wrote the paper, analyzed data had primary responsibility for the final content. AS designed the
449 research and analyzed data. RC performed data management and statistical analysis. MTR, DB and DKT
450 designed the research. PDS analyzed data and wrote the paper. ZD designed the research, obtained the
451 funding, and wrote the paper.

452
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538

539

540 References

541

- 542 1. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic
543 disease. *Curr Pharm Des.* 2009;15(13):1546-1558. doi:10.2174/138161209788168164
- 544 2. Bidu C, Escoula Q, Bellenger S, et al. The Transplantation of ω 3 PUFA-Altered Gut Microbiota
545 of fat-1 Mice to Wild-Type Littermates Prevents Obesity and Associated Metabolic Disorders. *Diabetes.*
546 2018;67(8):1512-1523. doi:10.2337/db17-1488
- 547 3. Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation:
548 nutritional implications for chronic diseases. *Biomed Pharmacother.* 2006;60(9):502-507.
549 doi:10.1016/j.biopha.2006.07.080
- 550 4. Bender N, Portmann M, Heg Z, Hofmann K, Zwahlen M, Egger M. Fish or n3-PUFA intake and
551 body composition: a systematic review and meta-analysis. *Obes Rev Off J Int Assoc Study Obes.*
552 2014;15(8):657-665. doi:10.1111/obr.12189
- 553 5. Abbott KA, Burrows TL, Acharya S, Thota RN, Garg ML. DHA-enriched fish oil reduces insulin
554 resistance in overweight and obese adults. *Prostaglandins Leukot Essent Fatty Acids.* 2020;159:102154.
555 doi:10.1016/j.plefa.2020.102154
- 556 6. Wang J, Zhang Y, Zhao L. Omega-3 PUFA intake and the risk of digestive system cancers: A
557 meta-analysis of observational studies. *Medicine (Baltimore).* 2020;99(19):e20119.
558 doi:10.1097/MD.00000000000020119
- 559 7. Mani V, Hollis JH, Gabler NK. Dietary oil composition differentially modulates intestinal
560 endotoxin transport and postprandial endotoxemia. *Nutr Metab.* 2013;10(1):6. doi:10.1186/1743-7075-
561 10-6
- 562 8. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin
563 resistance. *Diabetes.* 2007;56(7):1761-1772. doi:10.2337/db06-1491
- 564 9. Caesar R, Tremaroli V, Kovatcheva-Datchary P, Cani PD, Bäckhed F. Crosstalk between Gut
565 Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling. *Cell Metab.*
566 2015;22(4):658-668. doi:10.1016/j.cmet.2015.07.026
- 567 10. Monk JM, Liddle DM, Hutchinson AL, et al. Fish oil supplementation to a high-fat diet improves
568 both intestinal health and the systemic obese phenotype. *J Nutr Biochem.* 2019;72:108216.
569 doi:10.1016/j.jnutbio.2019.07.007
- 570 11. Durkin LA, Childs CE, Calder PC. Omega-3 Polyunsaturated Fatty Acids and the Intestinal
571 Epithelium-A Review. *Foods Basel Switz.* 2021;10(1). doi:10.3390/foods10010199
- 572 12. Wilson MJ, Sen A, Bridges D, et al. Higher baseline expression of the PTGS2 gene and greater
573 decreases in total colonic fatty acid content predict greater decreases in colonic prostaglandin-E2
574 concentrations after dietary supplementation with ω -3 fatty acids. *Prostaglandins Leukot Essent Fatty*
575 *Acids.* 2018;139:14-19. doi:10.1016/j.plefa.2018.11.001
- 576 13. Bellenger J, Bellenger S, Escoula Q, Bidu C, Narce M. N-3 polyunsaturated fatty acids: An
577 innovative strategy against obesity and related metabolic disorders, intestinal alteration and gut
578 microbiota dysbiosis. *Biochimie.* 2019;159:66-71. doi:10.1016/j.biochi.2019.01.017
- 579 14. Kaliannan K, Wang B, Li X-Y, Kim K-J, Kang JX. A host-microbiome interaction mediates the
580 opposing effects of omega-6 and omega-3 fatty acids on metabolic endotoxemia. *Sci Rep.* 2015;5:11276.
581 doi:10.1038/srep11276
- 582 15. Pu S, Khazanehei H, Jones PJ, Khafipour E. Interactions between Obesity Status and Dietary
583 Intake of Monounsaturated and Polyunsaturated Oils on Human Gut Microbiome Profiles in the Canola
584 Oil Multicenter Intervention Trial (COMIT). *Front Microbiol.* 2016;7. doi:10.3389/fmicb.2016.01612
- 585 16. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal
586 epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A.* 2013;110(22):9066-9071.
587 doi:10.1073/pnas.1219451110

- 588 17. Watson H, Mitra S, Croden FC, et al. A randomised trial of the effect of omega-3 polyunsaturated
589 fatty acid supplements on the human intestinal microbiota. *Gut*. 2018;67(11):1974-1983.
590 doi:10.1136/gutjnl-2017-314968
- 591 18. Ghosh S, DeCoffe D, Brown K, et al. Fish oil attenuates omega-6 polyunsaturated fatty acid-
592 induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. *PLoS*
593 *One*. 2013;8(2):e55468. doi:10.1371/journal.pone.0055468
- 594 19. Menni C, Zierer J, Pallister T, et al. Omega-3 fatty acids correlate with gut microbiome diversity
595 and production of N-carbamylglutamate in middle aged and elderly women. *Sci Rep*. 2017;7(1):11079.
596 doi:10.1038/s41598-017-10382-2
- 597 20. Flynn KJ, Ruffin MT, Turgeon DK, Schloss PD. Spatial Variation of the Native Colon
598 Microbiota in Healthy Adults. *Cancer Prev Res Phila Pa*. 2018;11(7):393-402. doi:10.1158/1940-
599 6207.CAPR-17-0370
- 600 21. Sidahmed E, Cornellier ML, Ren J, et al. Development of exchange lists for Mediterranean and
601 Healthy Eating diets: implementation in an intervention trial. *J Hum Nutr Diet Off J Br Diet Assoc*.
602 2014;27(5):413-425. doi:10.1111/jhn.12158
- 603 22. Djuric Z, Bassis CM, Plegue MA, et al. Colonic Mucosal Bacteria Are Associated with Inter-
604 Individual Variability in Serum Carotenoid Concentrations. *J Acad Nutr Diet*. 2018;118(4):606-616.e3.
605 doi:10.1016/j.jand.2017.09.013
- 606 23. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a Dual-Index
607 Sequencing Strategy and Curation Pipeline for Analyzing Amplicon Sequence Data on the MiSeq
608 Illumina Sequencing Platform. *Appl Environ Microbiol*. 2013;79(17):5112-5120.
609 doi:10.1128/AEM.01043-13
- 610 24. Pruesse E, Quast C, Knittel K, et al. SILVA: a comprehensive online resource for quality checked
611 and aligned ribosomal RNA sequence data compatible with ARB. *Nucleic Acids Res*. 2007;35(21):7188-
612 7196. doi:10.1093/nar/gkm864
- 613 25. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of
614 rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol*. 2007;73(16):5261-5267.
615 doi:10.1128/AEM.00062-07
- 616 26. Westcott SL, Schloss PD. OptiClust, an Improved Method for Assigning Amplicon-Based
617 Sequence Data to Operational Taxonomic Units. *mSphere*. 2017;2(2). doi:10.1128/mSphereDirect.00073-
618 17
- 619 27. Noriega BS, Sanchez-Gonzalez MA, Salyakina D, Coffman J. Understanding the Impact of
620 Omega-3 Rich Diet on the Gut Microbiota. *Case Rep Med*. 2016;2016:3089303.
621 doi:10.1155/2016/3089303
- 622 28. Calder PC. Is Increasing Microbiota Diversity a Novel Anti-Inflammatory Action of Marine n-3
623 Fatty Acids? *J Nutr*. 2019;149(7):1102-1104. doi:10.1093/jn/nxz043
- 624 29. Costantini L, Molinari R, Farinon B, Merendino N. Impact of Omega-3 Fatty Acids on the Gut
625 Microbiota. *Int J Mol Sci*. 2017;18(12). doi:10.3390/ijms18122645
- 626 30. Balfegó M, Canivell S, Hanzu FA, et al. Effects of sardine-enriched diet on metabolic control,
627 inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial.
628 *Lipids Health Dis*. 2016;15:78. doi:10.1186/s12944-016-0245-0
- 629 31. Backlund MG, Mann JR, Dubois RN. Mechanisms for the prevention of gastrointestinal cancer:
630 the role of prostaglandin E2. *Oncology*. 2005;69 Suppl 1:28-32. doi:10.1159/000086629
- 631 32. Zheng J, Hoffman KL, Chen J-S, et al. Dietary inflammatory potential in relation to the gut
632 microbiome: results from a cross-sectional study. *Br J Nutr*. Published online June 1, 2020:1-12.
633 doi:10.1017/S0007114520001853
- 634 33. Tu P, Bian X, Chi L, et al. Characterization of the Functional Changes in Mouse Gut Microbiome
635 Associated with Increased *Akkermansia muciniphila* Population Modulated by Dietary Black
636 Raspberries. *ACS Omega*. 2018;3(9):10927-10937. doi:10.1021/acsomega.8b00064

- 637 34. Roopchand DE, Carmody RN, Kuhn P, et al. Dietary Polyphenols Promote Growth of the Gut
638 Bacterium *Akkermansia muciniphila* and Attenuate High-Fat Diet-Induced Metabolic Syndrome.
639 *Diabetes*. 2015;64(8):2847-2858. doi:10.2337/db14-1916
- 640 35. Jayachandran M, Chung SSM, Xu B. A critical review of the relationship between dietary
641 components, the gut microbe *Akkermansia muciniphila*, and human health. *Crit Rev Food Sci Nutr*.
642 2020;60(13):2265-2276. doi:10.1080/10408398.2019.1632789
- 643 36. Anhe FF, Roy D, Pilon G, et al. A polyphenol-rich cranberry extract protects from diet-induced
644 obesity, insulin resistance and intestinal inflammation in association with increased *Akkermansia* spp.
645 population in the gut microbiota of mice. *Gut*. 2015;64(6):872-883. doi:10.1136/gutjnl-2014-307142
- 646 37. Willemsen LEM, Koetsier MA, van Deventer SJH, van Tol E a. F. Short chain fatty acids
647 stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2)
648 production by intestinal myofibroblasts. *Gut*. 2003;52(10):1442-1447. doi:10.1136/gut.52.10.1442
- 649 38. Crittenden S, Goepf M, Pollock J, et al. Prostaglandin E2 promotes intestinal inflammation via
650 inhibiting microbiota-dependent regulatory T cells. *Sci Adv*. 2021;7(7). doi:10.1126/sciadv.abd7954
- 651 39. Li Q, Zhang Q, Wang M, Zhao S, Xu G, Li J. n-3 polyunsaturated fatty acids prevent disruption
652 of epithelial barrier function induced by proinflammatory cytokines. *Mol Immunol*. 2008;45(5):1356-
653 1365. doi:10.1016/j.molimm.2007.09.003
- 654 40. Lallès J-P. Recent advances in intestinal alkaline phosphatase, inflammation, and nutrition. *Nutr*
655 *Rev*. 2019;77(10):710-724. doi:10.1093/nutrit/nuz015
- 656 41. Sanguansri L, Shen Z, Weerakkody R, Barnes M, Lockett T, Augustin MA. Omega-3 fatty acids
657 in ileal effluent after consuming different foods containing microencapsulated fish oil powder - an
658 ileostomy study. *Food Funct*. 2013;4(1):74-82. doi:10.1039/c2fo30133d
- 659 42. Zhang Y-G, Xia Y, Lu R, Sun J. Inflammation and intestinal leakiness in older HIV+ individuals
660 with fish oil treatment. *Genes Dis*. 2018;5(3):220-225. doi:10.1016/j.gendis.2018.07.001
661

Table 1. Baseline characteristics of Healthy Dietary Study participants by tertiles of colonic mucosal ω -3/ ω -6 PUFA (polyunsaturated fatty acids) ratios at baseline

Characteristic	Tertile 1, N = 28 ¹	Tertile 2, N = 29 ¹	Tertile 3, N = 31 ¹	p-value ²
ω -3/ ω -6 PUFA ratio tertiles	<0.07	0.07-0.27	>0.27	
Age (years)	54 (48, 59)	53 (49, 57)	56 (48, 62)	0.79
Body Mass Index (kg/m ²)	26.1 (23.1, 29.5)	27.2 (23.4, 32.0)	26.9 (23.2, 28.8)	0.32
Female	21 (75%)	22 (76%)	22 (71%)	0.94
Nonsteroidal anti-inflammatory drug (NSAID) use	5 (18%)	8 (28%)	3 (9.7%)	0.14
Lipopolysaccharide (LPS) binding protein (μ g/ml serum)	15 (12, 24)	15 (12, 19)	15 (11, 21)	0.91
Prostaglandin E ₂ (colon, pg/mg protein)	16 (10, 26)	12 (4, 23)	14 (7, 24)	0.38
Shannon Index	2.52 (2.39, 2.63)	2.48 (2.37, 2.55)	2.33 (2.02, 2.52)	0.03
Serum ω -3 PUFA ² (%)	3.16 (2.67, 3.62)	3.38 (2.77, 3.73)	4.33 (3.50, 5.33)	<0.001
Serum ω -6 PUFA ² (%)	37 (35, 43)	36 (33, 43)	38 (33, 43)	0.62
Serum ω -3/ ω -6 PUFA ratio	0.08 (0.07, 0.10)	0.09 (0.08, 0.10)	0.11 (0.09, 0.14)	<0.001
Dietary ω -3 PUFA (g/day)	0.75 (0.58, 0.87)	0.74 (0.56, 1.04)	0.79 (0.56, 1.02)	0.88
Dietary ω -6 PUFA (g/day)	6.94 (5.97, 8.14)	6.75 (5.87, 8.38)	6.20 (5.44, 7.47)	0.32
Dietary ω -3/ ω -6 PUFA ratio	0.11 (0.09, 0.13)	0.11 (0.10, 0.14)	0.13 (0.10, 0.16)	0.24
Colon tissue Saturated fatty acids ² (%)	32.1 (27.0, 34.8)	32.6 (31.4, 35.3)	32.6 (31.3, 33.1)	0.21
Colon tissue Monounsaturated fatty acids ² (%)	31.4 (28.1, 36.1)	32.2 (28.7, 33.9)	31.6 (29.1, 32.5)	0.91

¹ Summary statistics are presented as median (IQR); n (%). The statistical tests performed were the Kruskal-Wallis test or the chi-square test of independence for categorical variables.

² Fatty acids in serum and colon tissue are shown as percent of total fatty acids analyzed.

Table 2. Changes in dietary, serum and colonic mucosal fatty acid content before and after intervention in the Healthy Eating Study by diet arm assignment.

Fatty acid %	Healthy Eating (n = 42)	Mediterranean (n = 44)	Total (n = 86)
	Median change ¹ (95 CI%) ²	Median change ¹ (95 CI%) ²	Median change ¹ (95 CI%) ²
MUFA ³ (%) (tissue)	0.67 (-0.44, 1.63)	0.36 (-1.10, 1.55)	0.50 (-0.34, 1.25)
MUFA ³ (%) (serum)	0.40 (-0.86, 1.52)	1.77 (0.60, 3.13)	1.06 (0.21, 1.91)
ω-6 PUFA ⁴ (%) (tissue)	-0.17 (-1.37, 0.88)	-0.29 (-1.22, 0.98)	-0.23 (-0.97, 0.54)
ω-3 PUFA ⁴ (%) (tissue)	0.42 (0.07, 0.73)	0.48 (0.17, 0.76)	0.44 (0.22, 0.66)
ω-3/ω-6 ratio (tissue)	0.01 (0.001, 0.02)	0.01 (0.006, 0.03)	0.01 (0.007, 0.02)
ω-6 PUFA ⁴ (%) (diet)	-0.20 (-0.91, 0.62)	-1.81 (- 2.50, -1.15)	-1.04 (-0.54, -1.54)
ω-3 PUFA ⁴ (%) (diet)	0.11 (0.005, 0.24)	0.07 (-0.11, 0.26)	0.08 (-0.007, 0.20)
ω-3/ω-6 ratio (diet)	0.02 (0.004, 0.03)	0.05 (0.02, 0.09)	0.03 (0.02, 0.05)
ω-6 PUFA ⁴ (% , serum)	-0.13 (-1.26, 1.01)	-1.73 (-2.92, -0.41)	-1.04 (-1.73, -0.25)
ω-3 PUFA ⁴ (% , serum)	0.26 (0.02, 0.67)	0.34 (-0.06, 0.71)	0.32 (0.10, 0.57)
ω-3/ω-6 ratio (serum)	0.01 (-0.001, 0.02)	0.01 (0.002, 0.02)	0.01 (0.003, 0.02)

¹Values are the change in mean percentages for each fatty acid.
²95% confidence intervals calculated with Wilcoxon signed rank test.
³ Monounsaturated fatty acid (MUFA)
⁴ Polyunsaturated fatty acid (PUFA)
 Bolded values are significant with P-value<0.05


Table 3. Linear regression modeling of colonic mucosal variables (ω -3/ ω -6 fatty acid ratios, PGE₂ concentration in colon, cyclooxygenase (COX)-1 and 2 gene expression in colon) at 6 months as a factor of log change in *Akkermansia* abundance levels in all 86 individuals after dietary intervention adjusting for baseline colonic mucosal variable values. The data shown is the adjusted β regression coefficient and 95% confidence interval (CI). The adjusted R² represents the fraction of variability in the colonic mucosal variable at 6 months that is explained by the linear regression model¹.

Characteristic	Change in ω -3 PUFA/ ω -6 PUFA ²	Change in PGE2	Change in COX-1	Change in COX-2
	Adjusted R ² =0.56	Adjusted R ² =0.58	Adjusted R ² =0.22	Adjusted R ² =0.22
Overall model				
Tissue n-3 PUFA/ n-6 PUFA (baseline)	0.70 (0.56, 0.84)			
Tissue PGE2 (baseline)		0.81 (0.63, 1.0)		
Tissue COX-1 (baseline)			0.75 (0.54, 1.0)	
Tissue COX-2 (baseline)				0.77 (0.57, 1.0)
<i>Akkermansia</i> (log change)	0.13 (0.02, 0.24)	-37 (-66, -6.8)	1.6 (-3.9, 0.64)	-0.19 (0.73, 0.35)
Dietary n-3 PUFA/ n-6 PUFA (after dietary intervention)	-0.01 (-0.10, 0.07)	5.6 (-17, 28)	-1.2 (-2.9, 0.54)	0.32 (-0.19, 0.83)


¹ Multivariate linear regression with colonic mucosal variable at 6 months as the dependent variable adjusting for baseline colonic mucosal variable value, log change in *Akkermansia*, dietary colonic ω -3/ ω -6 PUFA at baseline, age, sex, and BMI. Bolded values are significant in the model with P-value<0.05

² Abbreviations used are: polyunsaturated fatty acids (PUFA), Prostaglandin E2 (PGE2), Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2).

Figure 1. Alpha diversity, accessed by Shannon Index, across tertiles of A) dietary, B) serum and C) colonic mucosal ω -3/ ω -6 PUFA levels after 6 months of dietary intervention.



662 Figure 2. Between microbial community differences across tertiles of A) dietary, B) serum and C) colonic
663 mucosal ω -3/ ω -6 PUFA levels following dietary intervention. The circles represent the different tertiles of
664 ω -3/ ω -6 PUFA ratios in diet, serum and colon biopsies. Non-metric multidimensional scaling (NMDS).
665



666
667

Figure 3. Correlation between taxon abundance and dietary, serum and colonic mucosal ω -3/ ω -6 PUFA ratios before and after 6 months of dietary intervention.

